Main > ONCOLOGY (**) > Leukemia>Myeloid>Acute>IDH2+ R/R* > Treatment > Co: USA. C. Enasidenib

---

Co: USA. C. Enasidenib's subsections
(*) USA Approval Date: 2017. 08.01
Companion Diagnostics>
Company
Patent>Assignee; Claims; No.; Etc.
Patent>UpDate: 2018. 07.17.
PR Web-Site
TradeMark
TradeMark Web-Site
UpDate: 2017. 08.02

Co: USA. C. Enasidenib's products
This section has no products